CD320 Knockout K-562 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated via disruption of the CD320 gene in the K-562 chronic myelogenous leukemia (CML) cell line. This product provides a heterogeneous pool of edited cells for loss-of-function studies of the CD320 receptor, which is critical for cobalamin (vitamin B12) uptake and downstream metabolic processes.
K-562 cells are a pluripotent hematopoietic progenitor-like suspension line established from the pleural effusion of a 53-year-old female with CML in blast crisis. The BCR-ABL?Cpositive background confers constitutive tyrosine kinase activity, and the line retains the capacity to differentiate along erythroid, granulocytic, and monocytic lineages, making it a versatile model for studying hematopoiesis, leukemia biology, and metabolic regulation.
CD320 encodes the receptor for the transcobalamin II?Ccobalamin (TCN2?CB12) complex. Upon ligand binding, CD320 interacts with clathrin and the AP2 adapter complex to mediate endocytosis, delivering cobalamin to lysosomes for release into the cytosol. Intracellular cobalamin acts as an essential cofactor for methionine synthase (MTR), which remethylates homocysteine to methionine in the folate-dependent one?carbon cycle, and for methylmalonyl?CoA mutase (MUT), which converts methylmalonyl?CoA to succinyl?CoA. Disruption of CD320 therefore impairs TCN2?mediated uptake, reducing cofactor availability for both MTR and MUT, and perturbing homocysteine and methylmalonic acid homeostasis.
In the K-562 background, loss of CD320 provides a unique tool to dissect cobalamin-dependent metabolism in a leukemic hematopoietic environment. Because K-562 cells exhibit progenitor-like plasticity, the knockout population permits investigation of how compromised one?carbon metabolism and succinyl?CoA synthesis influence proliferation, differentiation, and survival programs driven by BCR?ABL signaling. This model is particularly relevant for studying the metabolic vulnerabilities of CML cells and for exploring the intersection of vitamin B12 trafficking with oncogenic signaling.
Typical applications include quantitative analysis of cobalamin uptake via radiolabeled or fluorescent B12, flow cytometric monitoring of surface CD320 loss, Western blotting and RT?qPCR profiling of downstream effectors (MTR, MUT, MTHFR, CBS), and functional assays for homocysteine, methylmalonic acid, and cell viability. These polyclonal knockout cells can also serve as a platform for drug?target validation, small?molecule screens modulating B12 pathways, and modeling the cblF type of combined methylmalonic aciduria and homocystinuria in a hematopoietic context. For further information or customized applications, please contact Ascent Research.
